Objective: Assess the long-term efficacy and safety of erenumab in patients with chronic migraine with acute medication overuse.
Background: Overuse of acute medication in patients with chronic migraine has been linked to greater pain intensity and disability and may diminish the effectiveness of preventive therapies.
Methods: This 52-week open-label extension study followed a 12-week double-blind placebo-controlled study in which patients with chronic migraine were randomized 3:2:2 to placebo or once-monthly erenumab 70 mg or 140 mg. Patients were stratified by region and medication overuse status. Patients received erenumab 70 mg or 140 mg throughout or switched from erenumab 70 to 140 mg (based on protocol amendment to augment safety data at higher dose). Efficacy was assessed in patients with and without medication overuse at parent study baseline.
Results: Of 609 patients enrolled in the extension study, 252/609 (41.4%) met the criteria for medication overuse at parent study baseline. At Week 52, the mean change in monthly migraine days from parent study baseline was -9.3 (95% confidence interval: -10.4, -8.1 days) in the medication overuse subgroup versus -9.3 (-10.1, -8.5 days) in the non-medication overuse subgroup (combined erenumab doses); proportion of patients achieving ≥50% reduction in monthly migraine days at Week 52 was 55.9% (90/161; 48.2%, 63.3%) versus 61.3% (136/222; 54.7%, 67.4%), respectively. Among baseline users of acute migraine-specific medication, the mean change in monthly migraine-specific medication days at Week 52 was -7.4 (-8.3, -6.4 days) in the medication overuse subgroup versus -5.4 (-6.1, -4.7 days) in the non-medication overuse subgroup. Most patients (197/298; 66.1%) in the medication overuse subgroup transitioned to non-overuse status by Week 52. Erenumab 140 mg was associated with numerically greater efficacy than erenumab 70 mg across all endpoints. No new safety signals were identified.
Conclusion: Long-term erenumab treatment demonstrated sustained efficacy and safety in patients with chronic migraine with and without acute medication overuse.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/head.14536 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genotypic Characterisation of Carbapenem-Resistant Enterobacteriaceae in a Tertiary Care Hospital in South India.
Cureus
December 2024
Medical Microbiology, Vinayaka Mission's Kirupananda Variyar Medical College and Hospital, Salem, IND.
Introduction The antimicrobial resistance of is variable and is influenced by both geographic location and regional antibiotic use. The overuse of antibiotics, especially in hospitalised patients, suppresses the growth and persistence of drug-resistant bacteria. This study aimed to detect the prevalence of carbapenem-resistant and the genes responsible for the resistance.
View Article and Find Full Text PDFReal-world clinical results of CGRP monoclonal antibody treatment for medication overuse headache of migraine without abrupt drug discontinuation and no hospitalization.
Heliyon
November 2024
Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Background: Abrupt discontinuation of overused medications is standard treatment for medication overuse headache (MOH), but discontinuation is difficult to maintain. The aim was to evaluate the real-world clinical results of anti-calcitonin gene-related peptide monoclonal antibody (CGRP-mAb) treatment for migraine with MOH without abrupt drug discontinuation and no hospitalization.
Methods: Data were collected before starting CGRP-mAb injections (baseline) and 1 month after each injection.
Community pharmacists' perceptions of their challenges in relation to older adults prescribed psychotropic medications: a focus-group study.
Int J Clin Pharm
December 2024
UNIV ANGERS, School of Pharmacy, Health Faculty, University of Angers, 49045, Angers, France.
Background: The management of psychotropic medication in older adults is a challenge for every healthcare professional, but data concerning community pharmacists are scarce in the literature.
Aim: Our objectives were i) to understand the difficulties encountered by community pharmacists in managing older adults on psychotropic medication, and ii) to identify potential solutions to the difficulties discussed.
Method: A qualitative study by focus group was proposed to all community pharmacists in the vicinity of the university hospital of Angers, France, between May and June 2023.
The burden of headache disorders in the adult population of Morocco: estimates, and a health-care needs assessment, from a cross-sectional population-based door-to-door survey.
J Headache Pain
December 2024
Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Edvard Griegs gate, Trondheim, Norway.
Background: We have previously shown headache disorders to be prevalent in in the adult general population of Morocco, especially migraine (30.8%) and headache on ≥ 15 days/month (H15+; 10.5%).
View Article and Find Full Text PDFEvaluation of dentists' clinical practices and antibiotic use in managing endodontic emergencies in Karachi, Pakistan: a cross-sectional survey.
BMC Oral Health
December 2024
Department of Surgery, Aga Khan University Hospital, Karachi, Pakistan.
Background: Endodontic emergencies, often presented as acute pain or swelling, constitute a substantial challenge in dental practice. While effective management emphasizes prompt intervention, antibiotics are typically indicated only when systemic signs and symptoms are present. There is limited research exists on evaluating the knowledge and clinical approach of dental practitioners in managing endodontic emergencies from our region of the world.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!